Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications (Q38444730)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 2015

Language	Label	Description	Also known as
English	Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications	scientific article published on June 2015

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

0 references

1 reference

Europe PubMed Central

Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications (English)

1 reference

Europe PubMed Central

3 September 2017

0 references

metabolic syndrome

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jonathan G Owen

1

1 reference

Europe PubMed Central

3 September 2017

Efrain Reisin

2

1 reference

Europe PubMed Central

3 September 2017

publication date

1 June 2015

1 reference

Europe PubMed Central

3 September 2017

Current Hypertension Reports

1 reference

Europe PubMed Central

3 September 2017

17

1 reference

Europe PubMed Central

3 September 2017

558

1 reference

Europe PubMed Central

3 September 2017

6

1 reference

Europe PubMed Central

3 September 2017

https://scigraph.springernature.com/pub.10.1007/s11906-015-0558-9

0 references

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

The key role of insulin resistance in the cardiometabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Prospective analysis of the insulin-resistance syndrome (syndrome X).

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Abdominal obesity and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Prevalence of childhood and adult obesity in the United States, 2011-2012

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Excess body mass index loss predicts metabolic syndrome remission after gastric bypass

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Mediterranean diet and metabolic syndrome: the evidence

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Reducing consumption of sugar-sweetened beverages is associated with reduced blood pressure: a prospective study among United States adults

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Medical therapy for the patient with obesity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Pathogenesis and pathophysiology of the cardiometabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Adipokines: novel players in resistant hypertension.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Obesity-associated hypertension: recent progress in deciphering the pathogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Vascular biology of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Local adipose tissue renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Increased adipose angiotensinogen gene expression in human obesity.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Efficacy of spironolactone therapy in patients with true resistant hypertension.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease?

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Mineralocorticoid receptor activation in obesity hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Relation of obesity and diet to sympathetic nervous system activity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Sympathetic overdrive and cardiovascular risk in the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Obesity-associated hypertension: new insights into mechanisms.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Leptin increasing sympathetic nerve outflow in obesity: A cure for obesity or a potential contributor to metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Obesity and adipokines: effects on sympathetic overactivity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Chronic leptin infusion increases arterial pressure.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Receptor-mediated regional sympathetic nerve activation by leptin.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

High plasma immunoreactive leptin level in essential hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Leptin and hypertension in obesity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Resistant hypertension, obstructive sleep apnoea and aldosterone.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Sympathetic neural mechanisms in obstructive sleep apnea.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Resistant hypertension and obstructive sleep apnea in the setting of kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Prevention of the Glucose Intolerance of Thiazide Diuretics by Maintenance of Body Potassium

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

ALLHAT, or the soft science of the secondary end point

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Pr

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Review of direct renin inhibition by aliskiren

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

β-blockers: a review of their pharmacological and physiological diversity in hypertension.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

beta-Blockers in hypertension: is carvedilol different?

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Treatment: special conditions. Metabolic syndrome: obesity and the hypertension connection

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice

1 reference

https://api.crossref.org/works/10.1007%2FS11906-015-0558-9

21 January 2018

THIAZIDE-INDUCED GLUCOSE INTOLERANCE TREATED WITH POTASSIUM

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of weight-reducing drugs in hypertensive patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adrenergic overdrive as the link among hypertension, obesity, and impaired thermogenesis: lights and shadows

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypokalemia, glucose intolerance, and hyperinsulinemia during diuretic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The mechanism of chlorothiazide-induced carbohydrate intolerance

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sympathetic activation in obese normotensive subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25916862

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11906-015-0558-9

1 reference

Europe PubMed Central

3 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38444730&oldid=1760126879"